As of 2026, clinical data regarding Aimovig (erenumab) and pregnancy remains limited but continues to grow through ongoing observational studies and pregnancy registries. Current medical consensus suggests that while animal studies have not shown direct fetal harm, the long half-life of Aimovig—approximately 28 days—means the drug remains in the system for nearly five months. Consequently, many healthcare providers recommend discontinuing Aimovig at least five months prior to planned conception to ensure the medication is fully cleared from the body before the critical stages of fetal development.
Managing chronic migraine during pregnancy presents a significant challenge for both patients and neurologists. Migraine is not merely a headache; it is a complex neurological condition that can be exacerbated by the hormonal fluctuations of pregnancy or, in some cases, may improve significantly during the second and third trimesters. Aimovig, a calcitonin gene-related peptide (CGRP) receptor antagonist, has revolutionized migraine prevention since its initial FDA approval in 2018. However, its use during the gestational period requires a careful weighing of maternal benefits against potential (though largely unproven) fetal risks.
The Mechanism of Aimovig and Placental Transfer
To understand the relationship between Aimovig and pregnancy, one must first understand how the drug functions. Aimovig is a human monoclonal antibody that binds to the CGRP receptor. CGRP is a potent vasodilator and plays a role in pain signaling. In the context of pregnancy, CGRP is also involved in maintaining normal blood pressure and vascular tone in the uteroplacental unit.
Monoclonal Antibodies and the Placenta
Aimovig is an IgG1 monoclonal antibody. Unlike small-molecule drugs that can diffuse easily across the placenta shortly after conception, large proteins like Aimovig typically do not cross the placenta in significant amounts during the first trimester. The transport of IgG antibodies across the placenta is an active process mediated by the neonatal Fc receptor (FcRn), which typically becomes most active during the second and third trimesters.
This biological timeline suggests that accidental exposure in the very early weeks of pregnancy may carry a lower risk of structural malformations than exposure later in pregnancy. However, because CGRP is involved in vascular regulation, there remains a theoretical concern that inhibiting the CGRP receptor during the later stages of pregnancy could interfere with the body's ability to respond to hypertensive challenges, such as preeclampsia.
Current Clinical Data and Animal Studies
As we move through 2026, the primary source of safety information comes from the Aimovig Pregnancy Registry and developmental and reproductive toxicology (DART) studies conducted on animals.
Findings from Animal Research
In studies involving cynomolgus monkeys, erenumab was administered throughout pregnancy at doses up to 10 times the maximum recommended human dose. These studies yielded no evidence of adverse effects on the fetus, no increased rate of structural abnormalities, and no impact on growth or postnatal development. While animal data is encouraging, it is not always perfectly predictive of human outcomes, which is why human registries are the "gold standard" for clinical decision-making.
Human Registry Data
The Aimovig Pregnancy Registry (and similar cross-product registries for CGRP inhibitors) tracks women who have been exposed to the drug shortly before or during pregnancy. The most recent data indicates that the rate of major birth defects in women exposed to CGRP inhibitors does not appear to be significantly higher than the background rate in the general population (approximately 2–4%). However, the sample sizes, while growing, are still considered relatively small by epidemiological standards, leading to a "cautious-by-default" approach among clinicians.
The "Washout" Period: Planning for Conception
For many patients, the most critical question is when to stop treatment. Because Aimovig has a half-life of 28 days, it takes approximately five half-lives—or 140 days—for the drug to be virtually eliminated from the bloodstream.
Why the 5-Month Rule Matters
- Total Clearance: Stopping the medication five months before trying to conceive ensures that no circulating erenumab is present when the embryo begins organogenesis.
- Stability Check: This period also allows the patient and their neurologist to assess how the migraine condition responds to the absence of the drug. If migraines return with high frequency or intensity, alternative, pregnancy-safe management strategies can be implemented before the stress of pregnancy begins.
- Hormonal Transition: Pregnancy itself causes a massive shift in estrogen levels. For about 60–70% of women, migraine frequency naturally decreases during pregnancy. The five-month washout period helps bridge the gap to this natural "hormonal protection."
Risks of Untreated Migraine During Pregnancy
It is vital to balance the risks of medication against the risks of untreated chronic migraine. Severe, frequent migraine attacks during pregnancy are not benign. They are associated with several maternal and fetal complications, including:
- Gestational Hypertension: Chronic pain and the associated stress response can contribute to elevated blood pressure.
- Preeclampsia: Some studies have shown a higher risk of preeclampsia in women with high-frequency migraines.
- Low Birth Weight: Frequent severe attacks can lead to poor maternal nutrition, dehydration, and sleep deprivation, all of which may impact fetal growth.
- Mental Health: The psychological toll of chronic pain can increase the risk of prenatal and postpartum depression and anxiety.
When discussing Aimovig and pregnancy with a provider, the conversation often shifts from "Is the drug safe?" to "Is the patient's migraine controlled enough to allow for a drug-free pregnancy?"
Comparison of Migraine Treatments in Pregnancy (2026 Guidelines)
The following table summarizes the 2026 clinical perspective on various migraine interventions compared to Aimovig.
| Treatment | Pregnancy Safety Profile (2026) | Recommended Action |
|---|---|---|
| Aimovig (Erenumab) | Limited human data; animal studies show no harm. | Discontinue 5 months before conception. |
| Acetaminophen | Generally considered the first-line acute treatment. | Use as needed at the lowest effective dose. |
| Magnesium Oxide | High safety profile; evidence-based for prevention. | Often recommended as a primary supplement. |
| OnabotulinumtoxinA (Botox) | Large molecular weight; unlikely to cross placenta. | Often used by specialists when benefits outweigh risks. |
| Triptans (e.g., Sumatriptan) | Extensive registry data; no evidence of major defects. | Preferred acute treatment if Acetaminophen fails. |
| NSAIDs (e.g., Ibuprofen) | Risks in 1st (miscarriage) and 3rd (ductus arteriosus) trimesters. | Avoid in 1st and 3rd trimesters. |
Breastfeeding and Aimovig
For patients who have delivered, the question of whether to resume Aimovig while breastfeeding is common. Monoclonal antibodies are large protein molecules that are present in human milk in very low concentrations. Furthermore, erenumab is likely to be partially or fully degraded in the infant’s gastrointestinal tract, meaning very little of the active drug would reach the infant's circulation.
Current 2026 guidelines suggest that while there is no specific data on the effects of Aimovig on the breastfed infant or on milk production, it is generally considered compatible with breastfeeding by many specialists, especially if the mother’s quality of life depends on the medication. Patients are encouraged to monitor their infants for any unusual symptoms, though none are expected based on the drug's pharmacology.
Navigating Accidental Exposure
If a patient becomes pregnant while taking Aimovig, the standard protocol involves:
- Immediate Discontinuation: Stop the injections as soon as the pregnancy is confirmed.
- Notification: Inform the neurologist and the obstetrician immediately.
- Registry Enrollment: Patients are encouraged to contact the Aimovig Pregnancy Registry to contribute to the collective knowledge that will help future patients.
- Enhanced Monitoring: Depending on the timing of the last dose, the obstetrician may recommend detailed anatomy scans during the second trimester, although this is often standard practice regardless of medication exposure.
Frequently Asked Questions
1. Does Aimovig cause infertility or affect my ability to get pregnant?
There is currently no clinical evidence to suggest that Aimovig or other CGRP inhibitors impact fertility in men or women. Animal studies did not show any impairment of fertility or reproductive performance. If you are experiencing difficulty conceiving, it is likely due to other factors and should be discussed with a reproductive endocrinologist.
2. I just took my Aimovig shot and found out I’m pregnant. Should I be worried?
While no drug exposure during pregnancy is entirely without risk, current data on erenumab exposure in early pregnancy is reassuring. Because it is a large protein, it does not easily cross the placenta during the first few weeks (organogenesis). Most reported cases of accidental exposure have resulted in healthy births. Speak with your doctor about participating in a registry to monitor your pregnancy.
3. Are there safer alternatives to Aimovig for migraine prevention during pregnancy?
Yes. Many physicians recommend "nutraceuticals" like Magnesium, Riboflavin (Vitamin B2), and Coenzyme Q10, which have varying degrees of evidence for migraine prevention and are generally considered safe. Non-pharmacological options such as Cefaly (nerve stimulation) or prenatal physical therapy and acupuncture are also common alternatives used in 2026.
4. When can I restart Aimovig after giving birth?
Resumption of Aimovig can usually occur immediately after delivery if you are not breastfeeding. If you are breastfeeding, many neurologists support restarting the medication due to its low bioavailability in breast milk, but this should be a shared decision between you, your neurologist, and your pediatrician.
5. Why do some doctors say 2 months and others say 5 months for the washout?
The five-month recommendation is based on the biological "rule of thumb" that it takes five half-lives for a drug to be 97–99% eliminated. Since Aimovig’s half-life is 28 days, five months (140 days) is the scientifically conservative window for complete clearance. Doctors recommending a shorter window may be prioritizing the mother's headache control or basing their advice on the fact that placental transfer is minimal in the very early stages of the first trimester.
Practical Recommendations for Patients
If you are currently taking Aimovig and considering pregnancy in the next year, take the following steps:
- Pre-conception Consultation: Schedule a joint meeting or coordinated care between your neurologist and your OB/GYN. Discuss your "Migraine Action Plan" for when you stop Aimovig.
- The Taper and Washout: Aim to have your last dose of Aimovig five months before you stop using contraception.
- Document Your Baseline: Keep a detailed headache diary during the washout period. This data will be invaluable if you need to justify more intensive treatments or interventions later in pregnancy.
- Optimize Lifestyle: Focus on "migraine hygiene"—consistent sleep, hydration, and stress management—to minimize the need for medication.
- Stay Informed: Clinical guidelines for Aimovig and pregnancy are updated as more registry data becomes available. Regularly check with the FDA or the American Headache Society for the latest safety updates.
